PRLD vs. PYXS, XBIT, NKTR, VSTM, AEON, NBTX, KMDA, AQST, FHTX, and RAPT
Should you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Pyxis Oncology (PYXS), XBiotech (XBIT), Nektar Therapeutics (NKTR), Verastem (VSTM), AEON Biopharma (AEON), Nanobiotix (NBTX), Kamada (KMDA), Aquestive Therapeutics (AQST), Foghorn Therapeutics (FHTX), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 8.4% of Pyxis Oncology shares are owned by company insiders. Comparatively, 79.5% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Pyxis Oncology had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 1 mentions for Pyxis Oncology and 0 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.00 beat Pyxis Oncology's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.
Pyxis Oncology has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.
Pyxis Oncology presently has a consensus target price of $8.50, suggesting a potential upside of 97.67%. Prelude Therapeutics has a consensus target price of $5.25, suggesting a potential upside of 28.99%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Prelude Therapeutics.
Prelude Therapeutics' return on equity of -52.60% beat Pyxis Oncology's return on equity.
Prelude Therapeutics received 7 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 78.26% of users gave Pyxis Oncology an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
Pyxis Oncology is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Pyxis Oncology beats Prelude Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Prelude Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prelude Therapeutics Competitors List
Related Companies and Tools
